Cv Sciences Stock News

Premium sleep aid supports better sleep by combining melatonin and cannabinoids SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "

CV Sciences, Inc. (OTCQB:CVSI) Q2 2023 Earnings Conference Call August 14, 2023 10:00 AM ET Company Participants Brendan Hawkins - IR Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participa

SAN DIEGO , Aug. 14, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and o

SAN DIEGO , Aug. 1, 2023 /PRNewswire/ --  CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and

CV Sciences, Inc. (OTCQB:CVSI) Q1 2023 Earnings Conference Call May 15, 2023 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary and Director Joerg Grasser - CFO Conference Call Participa

CV Sciences, Inc. (OTCQB:CVSI) Q4 2022 Earnings Call Transcript March 29, 2023 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary and Director Joerg Grasser - CFO Conference Call Partici

SAN DIEGO , March 24, 2023 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and

CV Sciences, Inc. (OTCQB:CVSI) Q3 2022 Earnings Conference Call November 14, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference Call Partic

CV Sciences, Inc. (OTCQB:CVSI) Q2 2022 Earnings Conference Call August 15, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO, Secretary & Director Joerg Grasser - CFO Conference Call Particip

CV Sciences, Inc. (OTCQB:CVSI) Q1 2022 Results Conference Call May 16, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Scott Fortune - ROTH

SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc.  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp c

WASHINGTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Cannabidiol (CBD) Market finds that increasing awareness of cannabidiol''s therapeutic benefits is expediting market growth. Primarily driven by increasing demand for cannabidiol (CBD) for health and wellness purposes is high, the total Global Cannabidiol (CBD) Market is estimated to reach USD 47.22 Billion by 2028, up from USD 4.9 Billion in 2021, at a compound annual growth rate (CAGR) of 21.3%. Furthermore, rising acceptance and use of CBD products due to government approvals to augment the growth of the Global Cannabidiol (CBD) Market, states Vantage Market Research, in a report, titled " Cannabidiol (CBD) Market by Source (Hemp, Marijuana), by Distribution Channel (Online, Offline), by End-Use (Medical, Personal Use, Pharmaceuticals, Wellness), by Region (North America, Latin America, Europe, Asia Pacific) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/cannabidiol-cbd-market-1252/request-sample (The Free Sample Of This Report Is Readily Available On Request).

After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in Dry January. Who Thought Of Laying Off Booze For A Month?

CV Sciences, Inc. (OTCQB: CVSI ) is launching +PlusCBD Pain Relief topicals . The San Diego-based supplier and manufacturer of hemp cannabidiol (CBD) products confirmed Tuesday that the new line of topicals consists of four unique over-the-counter products formulated to pinpoint sources of minor pain and aches . These products contain active ingredients such as warming camphor and cooling menthol along with premium hemp-derived CBD and other natural emollients for skin-softening effects. CV Sciences strives to create meaningful impacts on the health and wellness of all consumers, Joseph Dowling , CEO of CV Sciences told Benzinga. Our team is constantly deriving unique formulations and evaluating new ingredients to create products that relieve problems as specific as muscle and joint pain. The new PlusCBD Pain Relief Full story available on Benzinga.com

CV Sciences, Inc. (OTCQB:CVSI) is launching +PlusCBD Pain Relief topicals. The San Diego-based supplier and manufacturer of hemp cannabidiol (CBD) products confirmed Tuesday that the new line of topic